INTRODUCTION 24
In the past few decades BCG intravesical immunotherapy following transurethral resection (TURBT) 25 of non-muscle-invasive bladder cancer (NMIBC) has been established as the most effective adjuvant 26 therapy, significantly reducing tumour progression and local recurrence (1). Intravesical BCG 27 immunotherapy is arguably the most successful immunotherapy modality employed clinically to 28 date. However, since the discovery of its benefits in bladder cancer therapy in the 1970s (2), the 29 mechanisms of its actions have remained unclear. 30
As the bladder is an enclosed and confined compartment, BCG can be stored at high concentrations, 31 theoretically resulting in a durable and continuous exposure (although the vast majority of BCG is 32 cleared within several hours after instillation (3), some bacteria may persist in the bladder for many 33 weeks or months (4, 5)). Ideally, an intact immune system is also required for successful BCG 34 treatment; however, efficacy and safety have also been demonstrated in some groups of 35 immunologically compromised patients with bladder cancer (6). BCG induces a mass release of 36 cytokines and inflammatory cells into the bladder, and these cytokines have different roles, being 37 anti-neoplastic, inflammatory, or inhibitory. 38
Despite high clinical efficacy, BCG immunotherapy is associated with significant side effects from 39 local haematuria and dysuria, to life threatening sepsis (7). Such side effects often mean that 40 patients do not complete the full course of induction or maintenance, potentially leading to worse 41 outcomes: although generally considered safe, BCG has local and systemic side effects that lead to 42 treatment cessation in up to 30% of patients, or to a delay or reduction in the number of instillations 43 in 55-83% of patients (8). Therefore, although BCG is effective, it is only suitable for intermediate 44 and high risk NMIBC patients in which current guidelines recommend one immediate instillation of 45 chemotherapy post-TURBT, followed by a minimum of one year of BCG intravesical immunotherapy 46 or further instillations of chemotherapy (7). A better understanding of BCG's mechanism of action 47 may allow its anti-neoplastic actions to be isolated, potentially improving efficacy and ameliorating 48 side effects. Furthermore, some patients fail to respond to BCG treatment, and identifying these 49 patients at an early stage (when other treatments may be curative) remains difficult. There is 50 evidence to suggest that certain cytokines may be predictive of BCG efficacy, although such cytokine 51 profiles are not yet being used clinically. 52
For immunotherapy to be effective, three basic steps need to be fulfilled. Firstly, there must be 53 uptake of the therapeutic agent into the tumour cells. In the bladder, fibronectin is responsible for 54 the uptake of BCG (9, 10). Then, an immune response must be induced, either by direct activation in 55 There is a wealth of data regarding response to BCG as an anti-tuberculosis (TB) vaccine, and it is 88 increasingly recognised that IL-17 and the archetypal Th1 cytokine, IFNγ, are closely linked in the 89 response to BCG vaccine. Indeed, protective immunity is at least partially dependant on an effective 90 Th1 response (17), for which it is proposed that IL-17 is also required (18). IL-17 additionally has roles 91 in recruiting neutrophils through the induction of IL-8 (discussed later). IL-8 mediated neutrophil 92 recruitment has been proposed to be at the heart of the anti-tumour activity of BCG (19, 20) , and in 93 murine models IL-17 is required for BCG immunotherapy efficacy (21). Data from BCG vaccine 94 studies have shown that neutrophils are efficacious, but a strong prolonged recruitment is 95 associated with pathology (22); how this relates to the deleterious side effects of BCG 96
immunotherapy is yet to be determined. 97
It would seem unlikely that anti-tumour T cells are directly activated by BCG; rather, an indirect 98 activation by presentation of tumour antigens in an inflammatory setting (i.e. alongside the response 99 to BCG) could be possible, in which cytokines are essential. Likewise, the killing of tumour cells may 100 be incidental, i.e. they are killed by BCG-specific T cells if infected by BCG. Notwithstanding, the 101 ability of tumour cells to present antigen is associated with response to BCG immunotherapy (23, 102 24). 103
104

Cytokines in BCG 105
The large number of publications investigating cytokine involvement in BCG immunotherapy is 106 derived from the discovery of elevated urinary levels of macrophages, T cells, NK cells and dendritic 107 cells post BCG instillation (25, 26), which suggest infiltration of lymphocytes into the bladder wall. 108
The internalisation of BCG by tumour cells or normal urothelial cells is likely an early step in this 109 cascade (3), with the tumour/urothelial cells thereafter seemingly functioning like antigen-110 presenting cells (APCs) to induce cytokine production (27, 28). The rationale for investigating 111 cytokine therapy alone or the administration of cytokines alongside BCG stems from the observation 112 that live BCG creates the side effects, whilst cytokines alone are much better tolerated. 113
Furthermore, it is thought that live BCG is not required to induce the bladder inflammatory cascade 114 (29) (although live BCG is required to induce the APC-like characteristics described above). secretion following BCG is neutrophil-dependent, and this same study showed that neutrophils 240 stimulated by BCG were able to kill bladder cancer cells in a TRAIL-dependent manner. TRAIL seems 241 to be unique to the BCG immune response (urine samples from urinary tract infections found lower 242 levels of TRAIL (68) In particular, IL-2 and IL-8 are the most widely studied (see Table 2 higher levels of IL-2 in later instillations to be a strong predictive factor for a positive response to 282 BCG therapy (72). However, they also found that IL-2 concentrations are variable depending upon 283 the storage method of the urine samples: cytokine concentrations in urine samples before and after13 freezing were different, and storage temperature caused variability. Indeed, the small sample size 285 and differences in sampling make interpretation of these data difficult. Despite this, the suggestion 286 that IL-2 is a predictive factor for BCG is supported by other studies (72, 75, 77, 78). Interestingly, 287
Kaempfer et al. showed IL-2 gene expression in peripheral blood to be predictive of response (79); it 288 would be of great interest to assess whether this relationship exists in a larger cohort of patients and 289 using current methodologies. 290
Urinary TRAIL appears in increased levels in BCG-responsive patients compared non-responders (20, 291 68). As mentioned above, heat-killed BCG is also able to elicit comparable TRAIL/Apo-2L release from 292 neutrophils as viable BCG (20). The potential of altering TRAIL expression to enhance BCG effect has 293 also been proposed, for example by using a combination therapy of BCG and IFN-α, or even by direct 294 intravesical recombinant TRAIL instillation (68). As well as increasing efficacy, it may permit a 295 reduced BCG dose to achieve the same effects, thereby decreasing the potential for adverse effects. The future development of BCG immunotherapy for bladder cancer should therefore be directed 305 towards three objectives: 306
• Identifying patients most likely to benefit from treatment; 307
• Increasing efficacy using promotion and blockade of specific cytokines; 308
• Reducing side effects and improving tolerability. 309
Cytokines with possible predictive value have the potential to act as a screening method for patients 310 who may or may not succeed with BCG treatment: IL-2, IL-8, TRAIL and TNFα appear to have a 311 predictive relationship with BCG efficacy, with significantly higher IL-2 and IL-8 levels in responders 312 compared to non-responders (Table 2 ). These cytokines appear within 6 hours post-instillation, and 313 have strong positive correlations to successful BCG treatment and non-recurrence. However, these 314 data are not consistent and so have not yet reached clinical practice. More recently, the IL-6:IL-10 315 ratio has also demonstrated predictive utility (80). This area of research would benefit from further 316 clarification and confirmatory studies since it could lead to efficient tests to identify the subgroup of 317 patients who reap no benefit from BCG but whom suffer from side effects, in addition to reducing 318 the delay to efficacious treatment (and reducing cost). 319
The physiochemistry of the molecules being studied also needs to be considered and results 320 interpreted carefully -cytokines can be unstable in biological fluids (78) (although IL-8 appears to be 321 stable in urine for over 48 hours (73) shown to enhance BCG Th1 responses in preclinical models, with better tumour-free survival rates. 372
These studies also found significantly enhanced levels of Th1 responses, including higher levels of 373 IFN-γ, with the use of anti-IL-10 receptor 1 monoclonal antibody in mice models (62, 63, 93) . 374
Translating these promising findings from in vivo preclinical models into early-phase clinical trials 375 should be considered a priority for the field. Mechanisms specific to BCG, such as TRAIL, should also 376 be considered. Therefore, combining BCG with cytokine-specific blockade or promotion may 377 increase effectiveness. However, when altering cytokine activity, consideration should also be given 378 to side effects: increasing efficacy may reduce tolerability, and the two should be considered 379 together since non-compliance due to side effects would be counter-productive. 380
To reduce adverse effects, alternatives to live BCG have been suggested. Whilst utilising live BCG is 381 standard practice, it produces significant side effects; alternatively, cytokine-only therapy is much 382 better tolerated, although single cytokine therapy has not proved successful. Having identified 383 specific cytokines that are involved in the anti-tumour response, it would be useful to test instillation 384 of a combination of cytokines. It would also be valid to test the differences in efficacy and side 385 effects of dead versus live BCG, given that dead BCG also induces the necessary inflammatory 386 cascade, whilst live BCG is responsible for the side effects. If dead BCG produces a less effective 387 response, it could be feasible to supplement the response with single cytokine therapy or cytokine 388 promotion; alternatively, it may be valid to assess induction with live BCG and maintenance therapy 389 with dead BCG (10). 390
This review has a number of limitations. Firstly, we have used a non-systematic approach to try to 391 identify the most pertinent studies in the field, but undoubtedly we have not carried out an 392 exhaustive review of all studies in the field. Our non-systematic approach is also a reflection of the 393 heterogeneity of source data and publications, with such data acquired from multiple studies 394 (mostly small in size), each utilising different treatment regimens and procedures for cytokine 395 evaluation and measurement, making direct comparisons difficult. As discussed above, uniformity in 396 such methodology could greatly improve research in this area. Meta-analyses of data regarding the 397 most promising cytokines described above could be appropriate and valuable, but such analyses are 398 beyond the scope of this review. However, it is our opinion that a strategy of co-ordinated early-399 phase studies in combination with comprehensive laboratory-based analyses is required to progress 400 the field and to optimise the management of patients receiving BCG for NMIBC. Unfortunately, 401 research funding for bladder cancer is poor when compared to other common malignancies (94-96), 402 and this needs to be urgently addressed before such progress can be made. 403
CONCLUSION 405
The mechanism of action for BCG is complex and variable, and a full understanding remains elusive. 406
It is likely that many elements of the immune system respond to BCG instillation; however, which of 407 these are necessary for the clinical efficacy of BCG immunotherapy remains to be answered. 408
Likewise, which of these are detrimental in terms of side effects is also unknown. Further research 409
should focus on combinations of BCG and cytokine therapy, as well as indicators of an individual's 410 response to treatment, such as predictive cytokines and genetic variants. Although these areas are 411 unlikely to be fully elucidated or utilised in clinical practice in the immediate future, further research 412 may shed light on determining how we can distinguish between patients who may benefit from BCG 413 treatment, how we can optimise BCG responses, and how we can reduce the side effects that limit 414 the use of BCG for many patients. 415
Introduction 417
• Intravesical instillation of Bacillus Calmette-Guerin (BCG) is an effective therapy for non-muscle-418 invasive bladder cancer. 419
• Intravesical BCG therapy is associated with significant side effects. 420
• The precise mechanism of action of BCG remains elusive. 421
• Understanding the mechanism of action may permit improved efficacy, improved patient 422 selection and a reduction in side effects. 423
The Immune Response 424
• The two main subsets of T cells are CD4 helper T cells and CD8 cytotoxic T cells, leading to the 425 concept of Th1 and Th2 subsets. 426
• Th1 cytokines produce pro-inflammatory responses; Th2 cytokines counteract the inflammatory 427 response and are also involved in antibody reactions. 428
Cytokines in BCG 429
• Following intravesical BCG therapy the cytokine milieu of the bladder and urine is complex and 430 variable. 431
• IL-10 and TRAIL may represent therapeutic targets for improving BCG efficacy. 432
Predictive cytokines 433
• IL-2, IL-8 and TRAIL show promise as predictive cytokines for BCG therapeutic responses. 434 Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for 
